This post was originally published on this site
(Reuters) – GlaxoSmithKline (NYSE:GSK) PLC announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc (NASDAQ:GILD) on Tuesday in relation to patent violations by Gilead’s Biktarvy, a medicine to treat human immunodeficiency virus.
The companies have agreed on a patent license and Gilead will also pay a 3% royalty on future U.S. sales of Biktarvy, GSK said in a statement.
